Romidepsin (FK228, Depsipeptide)

Catalog No.S3020 Synonyms: FR 901228, NSC 630176

Romidepsin (FK228, Depsipeptide) Chemical Structure

Molecular Weight(MW): 540.7

Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.

Size Price Stock Quantity  
USD 157 In stock
USD 477 In stock
USD 697 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • Effects of combination of bort/romidepsin on HDAC6 inhibition and activation of ER stress signaling. HA cells were treated with combination of 15 nM bortezomib and 5 nM romidepsin or either drug alone for 24 hr. Expression of CHOP/GADD153 (green signals) and cleaved PARP (red signals) was detected by immunofluorescent staining. DAPI (blue signals) stained the cell nuclei.

    Int J Cancer 2014 135(12):2950-61. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

    An HIV-Gag-SLYNTVATL-specific CTL clone was labeled with Alexa-Fluor555 conjugated cholera toxin subunit B either cultured with 500 nM SAHA or 25 nM romidepsin for 20 hours, or maintained as an untreated control. These effector cells were combined with SLYNTVATL peptide pulsed target cells, matched on the restricting allele, in a collagen matrix medium containing sytox green viability dye. These mixtures were then plated in three separate wells of an 8-well cover slip and imaged by time-lapse brightfield and fluorescent microscopy. A. Shown are representative fields of view from the no treatment (upper panel), 500 nM SAHA (middle panel), and 25 nM romidepsin (lower panel) conditions advancing in time from left to right. Time stamps are given in hh[ratio]mm format. Clones described in the results are indicated with yellow arrows and killed target cells are indicated with white arrows in the upper right panel.

    PLoS Pathog 2014 10(8), e1004287. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

  • PLZF-RARa–nonexpressing and -expressing PLZFRARβ3 cells were treated with 5 nmol/L romidepsin for the indicated time points. Induction of the DNA DSB marker γH2AX was measured by Western blotting. β-Actin was used as a loading control.

    Mol Cancer Ther 2013 12(8), 1591-604. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

    Impacts of chromopeptide A and FK228 on G2/M transition regulators. PC3 and LNCaP cells were treated with chromopeptide A or FK228 at indicated concentrations for 24 h, and cells lysates were immunoblotted with the indicated antibodies.

    Acta Pharmacol Sin, 2017, 38(4):551-560. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.
Features More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
Targets
HDAC1 [1]
(Cell-free assay)
HDAC2 [1]
(Cell-free assay)
36 nM 47 nM
In vitro

Unlike TSA, the active form redFK of Romidepsin strongly inhibits HDAC1 and HDAC2 with IC50 of 1.6 nM and 3.9 nM, respectively, but is relatively weak in inhibiting HDAC4 and HDAC6 with IC50 25 nM and 790 nM, respectively. Romidepsin is 17-23 times weaker than redFK in inhibiting these HDACs with IC50 of 36 nM, 47 nM, 510 nM, and 14 μM, respectively. Romidepsin treatment in HeLa cells induces histone acetylation and p21 expression with EC50 of 3.0 nM, more strongly than redFK with EC50 of 11 nM due to the instability of redFK. [1] In addition to G2/M arrest, Romidepsin treatment causes cyclin D1 downregulation and a p53-independent p21 induction, leading to inhibition of CDK and dephosphorylation of Rb resulting in growth arrest in the early G1 phase. [2] Romidepsin is 100 times more potent than TSA and 1,000,000 times more potent than butyrate in inhibiting the proliferation of the A549 cells. [3] Romidepsin inhibits the growth of U-937, K562, and CCRF-CEM cells with IC50 of 5.92 nM, 8.36 nM, and 6.95 nM, respectively. [5] Romidepsin promotes apoptosis in chronic lymphocytic leukemia (CLL) cells at a concentration corresponding to that at which H3 and H4 acetylation and HDAC inhibition occurs, selectively involving activation of caspase 8 and effector caspase 3, as well as down-regulation of c-FLIP protein. [6] In 11 of 13 (85%) renal cell carcinoma cell lines and in 16 of 37 (43%) other cancer cell lines, Romidepsin treatment up-regulates tumor death receptors, and potentiates natural killer (NK)-mediated tumor killing. [7] Romidepsin exhibits concentration-dependent cytotoxicity against a panel of mantle cell lymphoma (MCL) cell lines. [9]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SU-DHL4 MoS2R4VtdCCYaXHibYxqfHliQYPzZZk> NXvKcZJjOi53LUG1JI5O MY[3NkBp M{m5Tolv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? NWnkR|hSOjV5OUC5NFc>
U2932  NFP5[2ZE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MWWyMlUuOTVibl2= MUC3NkBp M3XIVYlv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? NGjqT|EzPTd7MEmwOy=>
OCI-LY7 NGDJVVdE\WyuIG\pZYJqdGm2eTDBd5NigQ>? Mo\CNk42NTF3IH7N Mnq2O|IhcA>? NF6weGRqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi NV\zNpc5OjV5OUC5NFc>
Farage MVPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NX[zPYI5Oi53LUG1JI5O M1LzWVczKGh? MlHRbY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? M{j4eFI2PzlyOUC3
LY7/EBV NVjYV2FQS2WubDDWbYFjcWyrdImgRZN{[Xl? MU[yMlUuOTVibl2= NWnUVZM5PzJiaB?= M4S2bYlv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? MWWyOVc6ODlyNx?=
U2932/EBV NFr0O4pE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MUGyMlUuOTVibl2= MVy3NkBp MVXpcoR2[2W|IHP5eI91d3irY3n0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh MkG1NlU4QTB7MEe=
HCT116 Mn7nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVK2[WlYPS13MECwJI5O NHzyOW4zPCCq NVHjT5N4TE2VTx?= NIHuWYlqdmS3Y3XzJINmdGxiZHXheIghcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> MX:yOVQ6OjVzNR?=
ACH-2 MXTGeY5kfGmxbjDBd5NigQ>? NIrNXngyNTlibl2= MmrCNlQhcA>? MkTUbY5lfWOnczDITXYuOSCHbo[g[ZhxemW|c3nvci=> M{nXSlI2OTR7NE[3
MCF-10A MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLOTWM2OD1yLkG3xtExNjBzIH7N MoTCNlQ6PTR6NU[=
MCF-7 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojITWM2OD1zLkGwxtExNjJyIH7N M4Xxc|I1QTV2OEW2
SK-BR-3 Ml\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTYTWM2OD1zLkCwxtExNjN3IH7N NIPJXnkzPDl3NEi1Oi=>
MDA-MB-231 NEi1WWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTBwNklCtVAvOTRibl2= NXPPboFnOjR7NUS4OVY>
PC3 NF7R[4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjXNZhiUUN3ME2xMlY2yrFyLkO1JI5O NXv2SHFQOjR7NUS4OVY>
HCT116 NIrqe|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnGfpZKSzVyPUGuNFDDuTBwMECgcm0> NVvxfHJZOjR7NUS4OVY>
HCT116-p21-/- NVjJXWg{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTFwMkdCtVAvOzdibl2= NV\3V5FFOjR7NUS4OVY>
S1 M4K3Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHITWM2OD15Lk[3xtExNjJ7IH7N NIH2XVEzPDl3NEi1Oi=>
SW620 M1f3[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTBwOURCtVAvOjlibl2= MlvmNlQ6PTR6NU[=
LOX-IMVI NFLE[mxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTBwOEhCtVAvODNibl2= MmH2NlQ6PTR6NU[=
UACC-62 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHDWlI4UUN3ME2wMlU3yrFyLkG2JI5O NFXTe2kzPDl3NEi1Oi=>
MDA-MB-435 Mn;CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrzTWM2OD1yLkmwxtExNjB4IH7N NGjzVY4zPDl3NEi1Oi=>
SF-295 NXyxR5p1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\OXmlEPTB;MD64POKyOC5zNTDuUS=> Mn;qNlQ6PTR6NU[=
A549 NYfFW3BWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTFwMkdCtVAvOjRibl2= M1HtPFI1QTV2OEW2
H460 M4\hTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFWwT3pKSzVyPUKuOVjDuTBwOECgcm0> NFuw[4QzPDl3NEi1Oi=>
EKVX NXTLV4VWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTFwM{RCtVAvOzRibl2= NFi3TYczPDl3NEi1Oi=>
H146 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTBwMkNCtVAvODdibl2= MUOyOFk2PDh3Nh?=
H526 M3PyTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\2TWM2OD1yLkG1xtExNjB|IH7N MnnENlQ6PTR6NU[=
HuT-78 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEH3do1KSzVyPUGuO|PDuTBwNESgcm0> MoTpNlQ6PTR6NU[=
HA MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DxflAvPjJ3LUGwcm0> NIfWcHQ1QCCq Mn\1bY5lfWOnczDhJJNq\26rZnnjZY51dHlic4Tyc45o\XJiaX7obYJqfGmxbjDv[kBk\WyuIIDyc4xq\mW{YYTpc44h[29vdILlZZRm\CC5aYToJIJwenSnen;tbYI> NWXtbFN[OjR5N{G1NVA>
MS-275 Mmj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3Syb|AvPjJ3LUGwcm0> NEe4UFE1QCCq Mm\ZbY5lfWOnczDhJJNq\26rZnnjZY51dHlic4Tyc45o\XJiaX7obYJqfGmxbjDv[kBk\WyuIIDyc4xq\mW{YYTpc44h[29vdILlZZRm\CC5aYToJIJwenSnen;tbYI> NUDXRpBLOjR5N{G1NVA>
CD4 T MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HGcFQ5KGh? MXjFR|UxRTRwNdMxNU4xKG6P NUS0R2lMOjR5MkK0OVQ>
CD4 T NGrTdJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVy0PEBp NVy1S2dwS0N3ME2xNFfDuTF{NjDuUS=> M3P1fFI1PzJ{NEW0
CD4+ T M1;mXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fGW2VEPTB;MzDuUS=> M3PrS|I1PDl3MUC1
A549 M3P6UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWSxNQKBmzFyMNMgcm0> MkLINlQwOzZxNEigbC=> M{S2b4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIgh[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= MVyyOFQ5PTd7OR?=
JJN3 Ml\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzWOnczPC92ODDo MUPFR|UxRDIkgJnuUVshPDkkgJno M{K3b|I1ODNyMUWw
OPM-2 NWnyR4V4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33jc|I1NzR6IHi= MWnFR|Uxez1z4pEJcm08KDR64pEJbC=> NYDNb2FPOjRyM{CxOVA>
RPMI-8226 NGPpUm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGGxRYozPC92ODDo NYHQZmM5TUN3MIO9NU456oDLbl27JFQ56oDLaB?= MYiyOFA{ODF3MB?=
U266 M4HTSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUCyOE81QCCq NXzOUpZHTUN3MIO9NVDjiImwTUugOFjjiImq M1uxNFI1ODNyMUWw
CA46 MUnBdI9xfG:|aYOgRZN{[Xl? MVu2JIg> MmfWbY5lfWOnczDicJVvfCCjcH;weI9{cXN? NVjjZ4F[OjN7Nk[xOlQ>
DG75 Ml:1RZBweHSxc3nzJGF{e2G7 M17mTFYhcA>? MUTpcoR2[2W|IH7vJIFxd3C2b4Ppdy=> MUeyN|k3PjF4NB?=
Ramos MYnBdI9xfG:|aYOgRZN{[Xl? MmXCOkBp MmrnbY5lfWOnczDlfJRmdnOrdnWgZZBweHSxc3nz NHy5OFMzOzl4NkG2OC=>
ST486 NXXsOmx2SXCxcITvd4l{KEG|c3H5 M3i1UFYhcA>? Mnj3bY5lfWOnczDlfJRmdnOrdnWgZZBweHSxc3nz M2nlR|I{QTZ4MU[0
HuT78 MUXBdI9xfG:|aYOgRZN{[Xl? MlPjNU8yOC9zMECgcm0> NFLySpM1QCCq MlrxbY5lfWOnczDhdI9xfG:|aYOgZZQhOSCwTR?= MmXBNlM2OzJ5M{K=
DpVp35 MkTZRZBweHSxc3nzJGF{e2G7 MU[xM|ExNzFyMDDuUS=> MVu0PEBp MkLDbY5lfWOnczDicJVvfCCjcH;weI9{cXN? MYmyN|U{Ojd|Mh?=
DpVp50 MkLxRZBweHSxc3nzJGF{e2G7 MnTKNU8yOC9zMECgcm0> MV:0PEBp MWjpcoR2[2W|IHLseY51KGGyb4D0c5Nqew>? MlvuNlM2OzJ5M{K=
DpP75  NEDKeFRCeG:ydH;zbZMhSXO|YYm= MUexM|ExNzFyMDDuUS=> NHPMXoc1QCCq NGD1TJBqdmS3Y3XzJIJtfW62IHHwc5B1d3Orcx?= NVrDZmc5OjN3M{K3N|I>
SKOV-3 NHnCNVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWmx5qCUOjCwTR?= NXPGWFB4PzJiaB?= MkXRSG1UVw>? MmKxdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCjbH;u[UBidmRiY3;tZolv\WRid3n0bEBkcXOybHH0bY4> MXSyN|AyODN2OB?=
Brca1 WT MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrKNJBTOeLCk{Kwcm0> MknRO|IhcA>? M{T4b2ROW09? NYjKfolbemWmdXPld{Bk\WyuII\pZYJqdGm2eTDhcI9v\SCjbnSgZ49u[mmwZXSge4l1cCClaYPwcIF1cW5? MoLaNlMxOTB|NEi=
Brca1 Null M17pSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\XNgKBmzJybl2= MXK3NkBp NGHJepVFVVOR MULy[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGGub37lJIFv\CClb33ibY5m\CC5aYToJINqe3CuYYTpci=> Ml3qNlMxOTB|NEi=
OVCAR-8  M4fVV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTGPYEy6oDVMkDuUS=> MU[3NkBp M3P5cmROW09? MmjmdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCjbH;u[UBidmRiY3;tZolv\WRid3n0bEBkcXOybHH0bY4> NI\3fFQzOzBzMEO0PC=>
NCI/ADR-RES NE\FTXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoC2NgKBmzJybl2= MWS3NkBp M{jRVmROW09? NYfRfXRDemWmdXPld{Bk\WyuII\pZYJqdGm2eTDhcI9v\SCjbnSgZ49u[mmwZXSge4l1cCClaYPwcIF1cW5? MXuyN|AyODN2OB?=
HCT116 MmXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfmNGRmPSCwTT21NEDPxE1? NInUWIozPCCq MVTEUXNQ NVfxVndGcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XJ? M1K4fFIzQTJ2OUW4
RKO NXjzZ44{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3mwWVUhdk1vNUCg{txO M2j4fVI1KGh? NVXjdpR7TE2VTx?= Ml[xbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> MUCyNlkzPDl3OB?=
CO115 M2jQOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33Bd|Uhdk1vNUCg{txO NHuxXYMzPCCq NHXCTIdFVVOR NVLtOFNIcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XJ? NIDufZAzOjl{NEm1PC=>
HFS M4rnfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUe1JI5O NV\jepBFOjRxNEivO|IhcA>? NEPwPGVqdmirYnn0d{Bk\WyuIHfyc5d1cCC2aX3lMYRmeGWwZHXueIx6 Mn;QNlIyODZ{OEK=
LNCaP NGH0dnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXW1JI5O MVSyOE81QC95MjDo NUPBfYRrcW6qaXLpeJMh[2WubDDndo94fGhidHnt[U1l\XCnbnTlcpRtgQ>? NHLWOlIzOjFyNkK4Ni=>
A549 Ml;PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYi1JI5O NFfIV4QzPC92OD:3NkBp NIDhcFdqdmirYnn0d{Bk\WyuIHfyc5d1cCC2aX3lMYRmeGWwZHXueIx6 M4f1RVIzOTB4Mkiy
697  MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTDTWM2OOLCiU5ihKkzNjYEoH7N NXTrTmhtOjF3M{iyNVY>
697-R NEn2eGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVO0RY1NUUN3MPMAjV3jiIl6LkdCpI5OyqB? M2[weFIyPTN6MkG2
HUT78 NGHwXnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjwfoVKSzVyPUGgcm0> M1;YbVIyOTl6NUS1
THJ-16T M1vWNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlm0NUBvVQ>? NVzQfHhiOjRiaB?= M3LVb4lvcGmkaYTzJINmdGxiZ4Lve5Rp MmC1NlA5OTB3Nki=
HCT116 NV;3fIx3TnWwY4Tpc44hSXO|YYm= NWnV[VluOjBibl2= M3jSVVghcA>? MonDcY9lfWyjdHXzJJRz[W6|Y4LpdJQhdGW4ZXzzJIZweiCqdX7kdoVleyCxZjDn[Y5meyCrbjDlbZRp\XJiZHny[YN1cW:w MYeyNFc{QTR3NB?=
B104  NUj1fGliTnWwY4Tpc44hSXO|YYm= M1XKW|Ihdk1? MUKyOE81QC95MjDo MlW4bY5kemWjc3XzJJRp\SC|dYLmZYNmKGW6cILld5Nqd25ib3[gR2QzOMLi M2jMOVIxPjh4NUC1
HL-60  NGDKPIVEgXSxdH;4bYNqfHliQYPzZZk> MlzTNU02ODBibl2= M{DqWlI1KGh? NHrrOFRqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi NFfrXogzODZ{NEG2Ny=>
HP100 MmnUR5l1d3SxeHnjbZR6KEG|c3H5 NIrqU2cyNTVyMDDuUS=> NVnOO4JvOjRiaB?= MorTbY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? MYCyNFYzPDF4Mx?=
HL-60  NHfPWnFHfW6ldHnvckBCe3OjeR?= NUm4OWViOTBibl2= NXPXbpdOPC94L{G2JIg> MlfzbY5lfWOnczD0bIUh\2WwZYLheIlwdiCxZjDofYRzd2enbjDw[ZJwgGmmZTDmdo9uKDSq NUjtU4hLOjB4MkSxOlM>
HP100 NX60XXJrTnWwY4Tpc44hSXO|YYm= Mo[4NVAhdk1? M1TOSlQwPi9zNjDo NH23PGZqdmS3Y3XzJJRp\SCpZX7ldoF1cW:wIH;mJIh6\HKxZ3XuJJBmem:6aXTlJIZzd21iNHi= MXOyNFYzPDF4Mx?=
HL-60  M2XnbWZ2dmO2aX;uJGF{e2G7 NUO4R|BZOTBvNUCwJI5O MYm0JIg> M3\XO4Rm[3KnYYPld{B1cGViaHnzeI9v\SCmZXHj[ZR6dGG|ZTCoTGRCSyliYXP0bZZqfHoEoB?= M3\QR|IxPjJ2MU[z
HP100 M{\tNmZ2dmO2aX;uJGF{e2G7 MX6xNE02ODBibl2= MoSyOEBp MlPZ[IVkemWjc3XzJJRp\SCqaYP0c45mKGSnYXPleJlt[XOnIDjISGFEMSCjY4Tpeol1gcLi NEj1[YMzODZ{NEG2Ny=>
11z NUTpbWlbU2mwYYPlJGF{e2G7 Mo\EN{0yODBibl2= MUPy[YR2[2W|IFjERWMh\W68eX3heIlkKGGldHn2bZR6KCiLQ{WwxsA:KDZwNTFCtUAxNjZibn3vcE9NMQ>? NEfwUJEzODZyNUG0OC=>
SKOV-3 M1iyemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jNVFQwQC9zNjDuUS=> MXy0PEBp NID4XFJqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? MlrKNlA1ODR3NkS=
OVCAR-3 M4LjS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUW0M|gwOTZibl2= M{W5c|Q5KGh? Mlf2bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> M17XfVIxPDB2NU[0
HBL-2 M2\hRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fqNFIuOTBibl2= NGXTNGgzPCCq NWnIXHNGUUN3ME20MlMhdk1? MXmyNFA3QDB6MB?=
Jeko-1 NX7iZpZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nOUlIuPTBibl2= NVnTR3VkOjRiaB?= NEO3[4tKSzVyPUGxJI5O M{HpcFIxODZ6MEiw
Granta-519 MlTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXUbXo2NTRyIH7N MUeyOEBp Mn35TWM2OD13OD61JI5O NEnDT4MzODB4OEC4NC=>
L1236 NVLs[mtqS3m2b4TvfIlkcXS7IFHzd4F6 NGDJSZkyKG6PLUGwNEDPxE1? M2HjeVQ5KGh? MmGxSWM2OD1yLkC3JO69VQ>? NVLibHdPOTl{M{O0O|A>
L428 MX7DfZRwfG:6aXPpeJkhSXO|YYm= MWSxJI5ONTFyMDFOwG0> MoPHOFghcA>? NEWyd5FGSzVyPUCuOFMh|ryP M2m1b|E6OjN|NEew
KM-H2 M4TqbmN6fG:2b4jpZ4l1gSCDc4PhfS=> M4HVXFEhdk1vMUCwJO69VQ>? M4XlOFQ5KGh? M2rifGVEPTB;MD61PEDPxE1? M2LhW|E6OjN|NEew
L540Cy NYHH[ZFyS3m2b4TvfIlkcXS7IFHzd4F6 MVmxJI5ONTFyMDFOwG0> NEjrN|I1QCCq NGnyVI1GSzVyPUCuNVYh|ryP MV2xPVI{OzR5MB?=
G401 M3rtUGZ2dmO2aX;uJGF{e2G7 NYGxS25COTBibl2= M3\EWFI1NzR6L{eyJIg> MkS5SG1UVw>? MmDNbY5kemWjc3XzJGNFU05zQzDlfJBz\XO|aX;u MWmxPVIzOTV6Nh?=
STM91-01 MnHmSpVv[3Srb36gRZN{[Xl? MlHDNVAhdk1? NXjIOIRjOjRxNEivO|IhcA>? Mn76SG1UVw>? NV7Qc2hZcW6lcnXhd4V{KEOGS16xR{BmgHC{ZYPzbY9v MkLvNVkzOjF3OE[=
SJSC  NYK4SWxqTnWwY4Tpc44hSXO|YYm= Mn7ENVAhdk1? MkjLNlQwPDhxN{KgbC=> M2ewRmROW09? MXXpcoNz\WG|ZYOgR2RMVjGFIHX4dJJme3Orb36= M3jnPFE6OjJzNUi2
BT16  MkLiSpVv[3Srb36gRZN{[Xl? NIHHZZQyOCCwTR?= NXHqO2xmOjRxNEivO|IhcA>? MUjEUXNQ NXrZT|Z2cW6lcnXhd4V{KEOGS16xR{BmgHC{ZYPzbY9v NGfLWZUyQTJ{MUW4Oi=>
NCI-H1299 NFrncI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\yc2lEPTB;ND62xtExNjJibnevcYw> M1y1WVE6OTd7OEmw
NCI-2882 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3PVIVKSzVyPUGuOuKyOC5yNDDu[{9udA>? M{HxSFE6OTd7OEmw
HCC95 M2nabGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzLN|ZKSzVyPUKuOeKyOC5yNTDu[{9udA>? NGXEZpEyQTF5OUi5NC=>
NCI-H23 NYn5So43T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPpTWM2OD1{LkpCtVAvOiCwZz;tcC=> MlT0NVkyPzl6OUC=
NCI-H157 MmXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTDbm9DUUN3ME2xMlbDuTBwMEKgcocwdWx? MX:xPVE4QTh7MB?=
NCI-H460 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrZTWM2OD1{LkJCtVAvODdibnevcYw> Mo\iNVkyPzl6OUC=
NCI-H1975 MoCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jwVGlEPTB;MT6zxtExNjB2IH7nM41t MmXwNVkyPzl6OUC=
NCI-H820 M1;nSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXezPIhbUUN3ME2yMlTDuTBwMTDu[{9udA>? MoDhNVkyPzl6OUC=
NCI-H1650 NY[xV3ltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml[3TWM2OD12LkpCtVAvOyCwZz;tcC=> MlL2NVkyPzl6OUC=
DTC1 MoHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfLfW5KSzVyPUCuOVEhdk1? MlLwNVg2PjZ{NE[=
KAO MnTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3ruNmlEPTB;MD65NUBvVQ>? M2LUPVE5PTZ4MkS2
SU-CCS-1 NWnGZ|VCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrKTWM2OD1yLki5JI5O MV2xPFU3PjJ2Nh?=
SYO-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTBwNkegcm0> MWGxPFU3PjJ2Nh?=
FUJI Mn:4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTFwM{Ggcm0> MlXWNVg2PjZ{NE[=
SKNMC MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vHV2lEPTB;MT6xO{BvVQ>? Mkm0NVg2PjZ{NE[=
402-91 NEfGWY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\RVW9TUUN3ME2xMlI3KG6P MljSNVg2PjZ{NE[=
1765-92 NIe1TYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVSxZmdrUUN3ME2xMlc4KG6P M3TZOFE5PTZ4MkS2
JN-DSRCT-1 MoDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInnbXpKSzVyPUGuNlUhdk1? MlzqNVg2PjZ{NE[=
NMS-2PC Mm[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfnXHJKSzVyPUCuPFEhdk1? NFfBfFAyQDV4NkK0Oi=>
HL60 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\uSnhKSzVyPUGuPFYhdk1? M1rRZlE5PTZ4MkS2
A549 M4TqdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfrVVdqUUN3ME2zMlI1KG6P MmT4NVg2PjZ{NE[=
SW480 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHm3RXhKSzVyPUKuOlkhdk1? NHzCWHgyQDV4NkK0Oi=>
MCF7 NEXje4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXEW|dKSzVyPUOuOVUhdk1? NY\xelRbOTh3Nk[yOFY>
PC-3 NG\UOWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTJwNUGgcm0> NIPTRVgyQDV4NkK0Oi=>
MMRU MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPNSYtKSzVyPUKuOVchdk1? MkSwNVg2PjZ{NE[=
Hs68 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXFTWM2OD1-MUCgcm0> M2PtOVE5PTZ4MkS2
hMSC-001F MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV:xS25vUUN3ME2+NVAhdk1? Ml7mNVg2PjZ{NE[=

... Click to View More Cell Line Experimental Data

In vivo Romidepsin treatment potently inhibits the neovascularization of chick embryo and that of adult mice in the Matrigel plug assay. [4]Administration of Romidepsin at 0.1-1 mg/kg twice a week significantly prolongs the survival of mice bearing U-937 lymphoma, with median survival times of 30.5 (0.56 mg/kg) and 33 days (0.32 mg/kg), respectively (vs. 20 days in control mice). [5]

Protocol

Kinase Assay:

[1]

+ Expand

HDAC-inhibitory activity:

For the enzyme assay, 10 μL of [3H]acetyl-labeled histones (25,000 cpm/10 μg) are added to 90 μL of the HDAC enzyme fraction extracted from 293T cells overexpressing HDAC1 or HDAC2 in the presence of increasing concentrations of Romidepsin, and the mixture is incubated at 37 °C for 15 minutes. The enzyme reaction is linear for at least 1 hour. The reaction is stopped by the addition of 10 μL of concentrated HCl. The released [3H]acetic acid is extracted with 1 mL of ethylacetate, and 0.9 mL of the solvent layer is taken into 5 mL of aqueous counting scintillant II solution for determination of radioactivity. The IC50 values are determined from at least three independent dose-response curves.
Cell Research:

[3]

+ Expand
  • Cell lines: HL60, Jurkat, A549, and MCF-7
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to various concentrations of Romidepsin for 72 hours in 96-well plates. 20 μL of 5 mg/mL MTT solution in PBS is added to each well for 4 hours. After removal of the medium, 170 μL of DMSO is added to each well to dissolve the formazan crystals. The absorbance at 540 nm is determined. In addition, cells are incubated with trypan blue, and the numbers of blue (dead) cells and transparent (live) cells are counted in a hemocytometer. For cell cycle analysis, cells are incubated for 30 minutes in propidium iodide staining solution containing 0.05 mg/mL propidium iodide, 1 mM EDTA, 0.1% Triton X-100, and 1 mg/mL RNase A in PBS. The suspension is then passed through a nylon mesh filter and analyzed on a Becton Dickinson FACScan.


    (Only for Reference)
Animal Research:

[5]

+ Expand
  • Animal Models: Male scid mice inoculated i.p. with U-937 cells
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: ~1 mg/kg once or twice a week
  • Administration: Treated i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 10 mg/mL (18.49 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5%Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 540.7
Formula

C24H36N4O6S2

CAS No. 128517-07-7
Storage powder
in solvent
Synonyms FR 901228, NSC 630176

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01947140 Recruiting Lymphoid Malignancies|Multiple Myeloma|Lymphoma|Hodgkin Lymphoma|Non-hodgkin Lymphoma Jennifer Amengual|Columbia University September 9 2013 Phase 1|Phase 2
NCT02512497 Recruiting Cutaneous T-cell Lymphoma|T-Prolymphocytic Leukemia|T-Large Granulocytic Leukemia|T-Lymphoblastic Leukemia/Lymphoma|Peripheral T-Cell Lymphoma Ohio State University Comprehensive Cancer Center|Celgene Corporation December 8 2017 Phase 1
NCT00007345 Completed Cutaneous T Cell Lymphoma|Peripheral T Cell Lymphoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) March 8 2001 Phase 2
NCT00112463 Completed Adult Alveolar Soft-part Sarcoma|Adult Angiosarcoma|Adult Epithelioid Sarcoma|Adult Extraskeletal Chondrosarcoma|Adult Extraskeletal Osteosarcoma|Adult Fibrosarcoma|Adult Leiomyosarcoma|Adult Liposarcoma|Adult Malignant Fibrous Histiocytoma|Adult Malignant Hemangiopericytoma|Adult Malignant Mesenchymoma|Adult Neurofibrosarcoma|Adult Rhabdomyosarcoma|Adult Synovial Sarcoma|Gastrointestinal Stromal Tumor|Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Recurrent Adult Soft Tissue Sarcoma|Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Stage III Adult Soft Tissue Sarcoma|Stage IV Adult Soft Tissue Sarcoma National Cancer Institute (NCI) January 7 2005 Phase 2
NCT02850016 Recruiting Human Immunodeficiency Virus (HIV) Rockefeller University|University Hospital of Cologne|Aarhus University Hospital January 6 2017 Phase 2
NCT02181218 Recruiting Lymphoma T-Cell Cutaneous|Lymphoma T-Cell Peripheral|Hodgkin Disease|Lymphoma Large B-Cell Diffuse Washington University School of Medicine|Celgene February 4 2015 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) supplier | purchase Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) cost | Romidepsin (FK228, Depsipeptide) manufacturer | order Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID